trial
as of 2026-07-01A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.
NCTId NCT00077727
at a glance
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
107 (actual)
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Double
Start
2003-03
Primary completion
—
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Sponsors
Johnson & JohnsonLead Sponsor
Sites
0 total
Facts & assertions
3 sourced
Enrollment
107
Phase
PHASE3
Status
COMPLETED
relationships
The graph out of here
lead_sponsor
company
indication